众生药业7月28日在互动平台回答投资者提问时表示,公司持有注射用更昔洛韦及更昔洛韦原料药的批文,公司将基于市场情况安排生产。
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.